Journal article
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
H Brown, J Vansteenkiste, K Nakagawa, M Cobo, T John, C Barker, A Kohlmann, A Todd, M Saggese, J Chmielecki, A Markovets, M Scott, SS Ramalingam
Journal of Thoracic Oncology | Published : 2020
Abstract
Introduction: EGFR mutated (EGFRm) NSCLC tumors occasionally express programmed cell death ligand 1 (PD-L1), although frequency and clinical relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical outcomes following treatment with osimertinib or comparator EGFR tyrosine kinase inhibitors in the FLAURA trial (phase III, NCT02296125). Methods: Of 231 tissue blocks available from the screened population (including EGFRm-positive and -negative samples), 197 had sufficient tissue for PD-L1 testing using the SP263 (Ventana, Tucson, Arizona) immunohistochemical assay. Tumor cell (TC) staining thresholds of PD-L1 TC greate..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
The study (NCT02296125) was funded by AstraZeneca, Cambridge, United Kingdom, the manufacturer of osimertinib. The authors thank all the patients involved in the FLAURA study and their families, the study investigators, and the team at AstraZeneca; Bernadette Tynan, MSc, of iMed Comms, Macclesfield, United Kingdom, an Ashfield Company, part of UDG Healthcare plc, for medical writing support that was funded by AstraZeneca, Cambridge, United Kingdom, in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3); and Maiyan Chau for study conception and interpretation, and Hiten Meisuria and the Tagrisso Information Exploitation Management Team for assistance in data analysis.